Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well niraparib and dostarlimab work in treating patients with
uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and
remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP
inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that
may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a
class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat
cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating
patients with uterine serous carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Casey Cosgrove
Treatments:
Dostarlimab Immunoglobulin G Immunoglobulins Niraparib